Navigation Links
Pharmaceutical Industry Service Company Awarded The UK's Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
Date:4/20/2012

LONDON, April 21, 2012 /PRNewswire/ --

Medaxial, the healthcare value communication specialist, today announces that it has won a Queen's Award for Enterprise in recognition of its international trade achievements.

The Queen's Awards for Enterprise are the UK's most prestigious business accolade, bestowed by Her Majesty Queen Elizabeth II on a select number of companies who have achieved outstanding results in international trade, innovation or sustainable development.  The awards are announced each year on April 21, The Queen's birthday.

Medaxial provides value communication solutions to many of the best-known names in the pharmaceutical, medical devices and diagnostics industries, and has been particularly successful in developing a client base in Europe and the USA.  The company's portfolio of services includes landscape and competitor assessment, clinical trial optimisation advice, pricing research, revenue forecasting, value message development and testing, strategic market access consultancy, health economic modelling, value dossier development, value communication toolkits and a wide range of tactical sales tools.  

Reacting to the news, one of the founding directors of Medaxial, John Fanshawe, said, "We have always believed that Medaxial's unique value communication perspective helps our clients to prosper in what are very difficult market conditions.  With continued pressure on healthcare budgets and the ever-increasing cost of bringing products to market, most pharmaceutical, biotechnology and medical devices companies now recognise the critical importance of successfully communicating the value of their products to the stakeholders who are expected to pay for them.  We have remained faithful to our belief in the central importance of value communication, and have built a reputation within the global healthcare industry for combining a rigorous approach to science and health economics with world-class communication expertise."

Paul Mcloughlin, also a founding director, added, "As a British company competing against some major overseas players, we operate in a tough and unforgiving marketplace, so we are absolutely delighted to receive this recognition.  Our growth over recent years is a testament to our understanding of the healthcare industry and the issues it faces, our insight into the decision-making processes in global healthcare systems, and the innovative value communication solutions that we provide."

About Medaxial

Medaxial is a specialist value communication consultancy with more than 15 years' experience of serving the global healthcare industry.  The services the company offers are based on two core beliefs: First, that no activity is more important to innovative healthcare companies than the communication of product value; and second, that value communication is inextricably linked to pricing, reimbursement, stakeholder research, health economic research and clinical evidence generation.

Medaxial is the only consultancy specialising in value communication that offers health economic, pricing and market access services. The company's value communication perspective ensures that all activities are focused on the central task of communicating product value in order to optimise commercial success.

The result is a highly-focused portfolio of services that helps clients demonstrate the value of innovative medicines, medical devices and diagnostic technologies, based on robust scientific evidence and high-quality market research.  

Medaxial is headquartered in London, England, and has an office in New York City serving the North American marketplace.  

About the Queen's Awards

Click this link for more information about The Queen's Awards



'/>"/>
SOURCE Medaxial
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... and Markets has announced the addition of the "Vital Signs Monitoring ... Industry Forecast, 2014-2022" report to their offering. ... Vital signs monitoring market size was worth $3,694 ... growing at a CAGR of 5.8% from 2016 to 2022. ... in global vital signs monitoring devices industry. The blood pressure monitoring devices ...
(Date:1/18/2017)... SAN JOSE, Calif. , Jan. 18, 2017  Adaptive ... machines, announced today a new partnership with Hyatt Place ... guests by providing ASTI LectroFan sleep therapy machines in ... "Obviously one of the most important parts of having ... Wicks , general manager of Hyatt Place Nashville/Downtown. "We,re ...
(Date:1/18/2017)... LITTLE FALLS, N.J. , Jan. 18, 2017 /PRNewswire/ ... RGIN ), a biotechnology company specializing in the development ... health of damaged tissues and organs, recently reported the ... key milestones for 2017. As the Company ... 2016 has been a year of substantial accomplishments. The ...
Breaking Medicine Technology:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish ... a condensed version of the clinic’s leading recovery program. , “We know ...
(Date:1/19/2017)... ... 19, 2017 , ... Bio-Optronics Inc. is proud to announce ... designed to seamlessly integrate and streamline the way researchers prepare and conduct patient ... usability and improving efficiency significantly for users – a first in the CTMS ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree ... planning services to communities throughout eastern Georgia, is embarking on a charity effort ... Heart disease kills more Americans every year than anything else, yet risk factors ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Attorney Robert ... fifth consecutive year donated money to the Triumph Over Kid Cancer foundation. Each year, ... one of those children. James saw firsthand the effect of the critical funding gap ...
Breaking Medicine News(10 mins):